Hemab Therapeutics Holdings
COAG
39.29
-0.57
-1.43%
Hemab Therapeutics Holdings
US · COAG
#3007 by market cap
Listed 2026
39.29
-0.57
-1.43%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | 8.97M | 10.49M |
| Research & development | 41.41M | 59.63M |
| Operating profit | -50.38M | -70.12M |
| Pretax profit | -48.52M | -64.14M |
| Tax | 185.00K | -227.00K |
| Net profit | -48.71M | -63.91M |
| Basic EPS | -2 | -2 |
| Diluted EPS | -1.77 | -2.33 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.18M | 2.50M | 2.35M | 4.15M | 5.74M | 5.12M |
| Research & development | 12.87M | 14.56M | 18.10M | 19.46M | 20.34M | 24.64M |
| Operating profit | -16.06M | -17.06M | -20.45M | -23.61M | -26.08M | -29.76M |
| Pretax profit | -12.21M | -16.97M | -19.47M | -22.68M | -24.05M | -26.61M |
| Tax | 4.00K | 98.00K | -139.00K | 12.00K | 97.00K | 693.00K |
| Net profit | -12.21M | -17.07M | -19.33M | -22.69M | -24.15M | -27.30M |
| Basic EPS | 0 | 0 | 0 | -1 | -1 | -1 |
| Diluted EPS | -0.44 | -0.39 | -0.44 | -0.51 | -0.80 | -0.58 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 93.24M | 192.55M |
| Cash & ST investments | 88.33M | 185.49M |
| Inventory | -- | -- |
| Total assets | 96.28M | 194.78M |
| Total current liabilities | 6.69M | 10.68M |
| Short-term debt | 669.00K | 647.00K |
| Long-term debt | -- | -- |
| Total liabilities | 211,551,000.00 | 371,418,000.00 |
| Total equity | -115.27M | -176.64M |
| Retained earnings | -117.95M | -181.86M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | -- | -- | 192.55M | 169.43M | 464.00M | 438.16M |
| Cash & ST investments | -- | -- | 185.49M | 163.53M | 457.46M | 430.24M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | -- | -- | 194.78M | 175.26M | 467.78M | 442.71M |
| Total current liabilities | -- | -- | 10.68M | 13.19M | 12.94M | 12.94M |
| Short-term debt | -- | -- | 647.00K | 544.00K | 460.00K | 462.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | -- | -- | 371,418,000.00 | 373,876,000.00 | 13,510,000.00 | 13,443,000.00 |
| Total equity | -- | -- | -176.64M | -198.62M | 454.27M | 429.27M |
| Retained earnings | -- | -- | -181.86M | -204.55M | -228.70M | -256.00M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -45.59M | -61.48M |
| Depreciation & amortization | 248.00K | 304.00K |
| Free cash flow | -45.87M | -61.49M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 74.41M | 87.97M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | -15.33M | -16.40M | -16.71M | -21.58M | -22.64M | -28.29M |
| Depreciation & amortization | 77.00K | 76.00K | 76.00K | 73.00K | 75.00K | 75.00K |
| Free cash flow | -15.33M | -16.40M | -16.71M | -21.70M | -22.66M | -28.33M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | -- | -- | -- | 0 |
| Ending cash balance | 61.49M | 45.07M | 87.97M | 49.86M | 237.37M | 239.15M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -50.59 | -43.92 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 13.95 | 18.03 |
| Quick ratioi | 13.45 | 17.62 |
| Debt / assetsi | 1.79 | 0.63 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -18.32 | -21.78 |
| ROA %i | -- | -- | -43.92 | -40.68 | -17.79 | -21.11 |
| ROIC %i | -- | -- | -- | -- | -18.97 | -22.90 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | -- | 18.03 | 12.85 | 35.85 | 33.86 |
| Quick ratioi | -- | -- | 17.62 | 12.51 | 35.48 | 33.34 |
| Debt / assetsi | -- | -- | 0.63 | 0.61 | 0.22 | 0.22 |
| LT debt / equityi | -- | -- | -- | -- | 0.12 | 0.12 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Hemab Therapeutics Holdings discussion 0 comments